This company markets pharmaceutical solutions for anti-viral smallpox treatment. It’s based in New York.
Their antiviral is also approved for monkeypox.
This is the drug:
So the question is scale, if ‘we’ need it can it be made quickly. I hope for the sake of patients and shareholders the answer is yes.
Hello new to shares do you think this would be a good one for the moment